FATE
Price
$1.00
Change
-$0.01 (-0.99%)
Updated
Dec 26 closing price
Capitalization
115.35M
65 days until earnings call
Intraday BUY SELL Signals
MGX
Price
$1.70
Change
-$0.04 (-2.30%)
Updated
Dec 26 closing price
Capitalization
63.83M
Intraday BUY SELL Signals
Interact to see
Advertisement

FATE vs MGX

Header iconFATE vs MGX Comparison
Open Charts FATE vs MGXBanner chart's image
Fate Therapeutics
Price$1.00
Change-$0.01 (-0.99%)
Volume$991.92K
Capitalization115.35M
Metagenomi
Price$1.70
Change-$0.04 (-2.30%)
Volume$274.65K
Capitalization63.83M
FATE vs MGX Comparison Chart in %
FATE
Daily Signal:
Gain/Loss:
MGX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
FATE vs. MGX commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Buy and MGX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (FATE: $1.00 vs. MGX: $1.70)
Brand notoriety: FATE and MGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 59% vs. MGX: 66%
Market capitalization -- FATE: $115.35M vs. MGX: $63.83M
FATE [@Biotechnology] is valued at $115.35M. MGX’s [@Biotechnology] market capitalization is $63.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileMGX’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • MGX’s FA Score: 1 green, 4 red.
According to our system of comparison, both FATE and MGX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 4 TA indicator(s) are bullish while MGX’s TA Score has 5 bullish TA indicator(s).

  • FATE’s TA Score: 4 bullish, 3 bearish.
  • MGX’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, MGX is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а -4.76% price change this week, while MGX (@Biotechnology) price change was -3.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

FATE is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($115M) has a higher market cap than MGX($63.8M). FATE YTD gains are higher at: -39.394 vs. MGX (-52.909). MGX has higher annual earnings (EBITDA): -86.79M vs. FATE (-145.34M). FATE has more cash in the bank: 215M vs. MGX (184M). MGX has less debt than FATE: MGX (41.7M) vs FATE (79.2M). MGX has higher revenues than FATE: MGX (30.9M) vs FATE (7.14M).
FATEMGXFATE / MGX
Capitalization115M63.8M180%
EBITDA-145.34M-86.79M167%
Gain YTD-39.394-52.90974%
P/E RatioN/AN/A-
Revenue7.14M30.9M23%
Total Cash215M184M117%
Total Debt79.2M41.7M190%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
9
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATEMGX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 17 days ago
84%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
FATE
Daily Signal:
Gain/Loss:
MGX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NXGCF1.480.20
+15.53%
Nexgold Mining Corp
GTHP0.360.03
+8.27%
Guided Therapeutics, Inc.
BDOUY23.190.53
+2.34%
BDO Unibank Inc.
NGCRF0.60N/A
N/A
Nagacorp Ltd.
SLMNP850.00-20.00
-2.30%
LYONDELLBASELL ADVANCED POLYMERS INC.

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with CRBU. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-0.99%
CRBU - FATE
49%
Loosely correlated
-1.16%
CRSP - FATE
48%
Loosely correlated
-2.87%
RXRX - FATE
46%
Loosely correlated
-3.41%
ALLO - FATE
45%
Loosely correlated
-1.43%
MGNX - FATE
45%
Loosely correlated
-0.62%
More

MGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGX has been loosely correlated with BEAM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MGX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGX
1D Price
Change %
MGX100%
-2.30%
BEAM - MGX
53%
Loosely correlated
-0.57%
CRSP - MGX
52%
Loosely correlated
-2.87%
FATE - MGX
46%
Loosely correlated
-0.99%
CRBU - MGX
46%
Loosely correlated
-1.16%
CADL - MGX
45%
Loosely correlated
-1.15%
More